Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 6.9% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals Inc. (AMLX) is a pharmaceutical company focused on developing drug candidates for various medical conditions, with a recent focus on ALS treatment. The stock had a bullish movement today, reaching a 52-week high of $18.65.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 6.9% on Jun 25, 2026 18:06

• Amylyx Pharmaceuticals stock surged to a 52-week high following positive updates about its ALS drug, AMX0114, showing no serious safety issues in the Phase 1 LUMINA trial.
• The disclosure of presenting data from the trial at the ENCALS Meeting 2026 likely bolstered investor confidence in the company's drug pipeline.
• A financial institution maintaining a Buy rating and raising the target price to $23 also contributed to the optimistic sentiment, indicating strong market expectations for Amylyx Pharmaceuticals' future performance.
• Despite concerns about overvaluation, the encouraging developments surrounding the ALS drug and analyst positivity drove the stock to new highs, demonstrating investor enthusiasm for the company's potential breakthroughs in the medical field.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals stock hits 52-week high at $18.65

Amylyx Pharmaceuticals Inc. (AMLX) stock has reached a 52-week high of $18.65, though InvestingPro analysis suggests it is overvalued. The company has shown significant gains over the past year, with a 171.57% return, and continues to advance its drug candidates despite a recent earnings miss, with analysts maintaining positive ratings due to upcoming trial results.

https://www.investing.com/news/company-news/amylyx-pharmaceuticals-stock-hits-52week-high-at-1865-93CH-4761006

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Amylyx Pharmaceuticals (NASDAQ: AMLX) announced that it will present data from its Phase 1 LUMINA trial of AMX0114 for ALS at the ENCALS Meeting 2026. The initial data from Cohort 1 showed AMX0114 had no drug-related serious adverse events and no serious neurological adverse events, supporting continued evaluation at higher doses. The LUMINA study is a multinational, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in people with ALS, and Cohorts 1 and 2 are fully enrolled, with Cohort 3 currently enrolling.

https://www.biospace.com/press-releases/amylyx-pharmaceuticals-to-present-data-from-first-in-human-dose-ranging-phase-1-lumina-trial-of-amx0114-in-als-at-encals-2026

Amylyx says ALS drug AMX0114 showed no serious safety issues

Amylyx Pharmaceuticals announced that its investigational ALS drug, AMX0114, showed no drug-related serious adverse events or serious neurological adverse events in the lowest dose cohort of its Phase 1 LUMINA trial. The company will present these findings at the ENCALS Meeting 2026, with evaluation continuing at higher dose levels. AMX0114 is an antisense oligonucleotide targeting calpain-2, a driver of axonal degeneration in ALS, and has U.S. FDA Fast Track designation.

https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-to-present-data-from-first-in-human-dose-yhflb6ijs451.html

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR

This document is a statement of changes in beneficial ownership of securities for George M. Milne Jr., a Director at Amylyx Pharmaceuticals. It confirms the filing of Form 4, which details changes in his holdings of company stock.

https://www.moomoo.com/news/notice/307487706/amylyx-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of

Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23

Goldman Sachs has maintained a Buy rating for Amylyx Pharmaceuticals (AMLX.US) and increased its target price to $23. This revised target price suggests a potential upside of 40.5% from the company's previous closing price. The adjustment reflects Goldman Sachs' continued positive outlook on the pharmaceutical company.

https://www.moomoo.com/news/post/71732915/goldman-sachs-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-raises

Trending Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 6.5% Today

Johnson Controls International plc ($JCI) Stock Forecast: Down 5.0% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 5.5% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 6.7% Today

Unity Software ($U) Stock Forecast: Up 5.3% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 7.3% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.4% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Up 5.3% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.2% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.5% Today

Amylyx Pharmaceuticals Price History

21.04.2026 - AMLX Stock was up 5.5%

• The positive news of the peer-reviewed publication of Phase 2 trial data for AMX0035 in treating Wolfram syndrome likely fueled the bullish movement in AMLX stock. The results, showing stabilization or improvement in various health parameters, have increased investor confidence in the company's drug pipeline.
• The reaffirmation of a Buy recommendation by B of A Securities has further bolstered investor sentiment towards Amylyx Pharmaceuticals, suggesting optimism about the company's future performance.
• The filing of an amended Schedule 13G/A by Perceptive Life Sciences Master Fund, Ltd., reporting a significant passive stake in AMLX, may have also contributed to the bullish movement by signaling institutional investor interest and support in the company's potential growth prospects.

18.04.2026 - AMLX Stock was down 5.1%

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

09.05.2026 - AMLX Stock was up 5.0%

• The increase in AMLX stock price today may be linked to the positive response following the news of directors receiving significant stock options, indicating a strong belief in the company's future performance.
• Ongoing stock option grants to key individuals within the company reflect a confidence in Amylyx Pharmaceuticals' long-term growth and success, which likely resonated positively with investors.
• Further adding to the optimistic sentiment, the announcement of a $6.5 million class action settlement for investors who acquired AMLX securities during a specific period could have provided stability and reassurance to the market, contributing to the upward movement in the stock.
• In summary, the combination of favorable internal developments like stock option grants and the resolution of legal matters through the settlement likely boosted investor confidence and drove the bullish trend in AMLX stock today.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

10.05.2026 - AMLX Stock was up 7.0%

• The positive sentiment surrounding the company's presentation at ENDO 2026, where they discussed the burden of post-bariatric hypoglycemia (PBH) and the design of their Phase 3 LUCIDITY trial for avexitide, a promising GLP-1 receptor antagonist, could be a factor behind the bullish movement in AMLX stock.
• The grant of stock options to various directors, including George M. Milne Jr., Karen Firestone, Paul R. Fonteyne, and Bernhardt G. Zeiher, might have also influenced the positive market sentiment, indicating confidence in the company's future and potential growth.
• These stock options grants could be perceived by investors as a demonstration of commitment from the directors, aligning their interests with those of the company. This alignment likely contributed to boosting investor confidence in Amylyx Pharmaceuticals and driving the bullish movement in AMLX stock.

23.05.2026 - AMLX Stock was up 5.2%

• AMLX saw a strong bullish movement during the recent session.
• A reputable investment firm maintained a Buy rating for AMLX and adjusted its target price to $23, suggesting a potential upside of 40.5%.
• Analysts anticipate positive earnings, with a consensus price target range of $20.00 to $25.00, mostly recommending a "Buy" for the stock.
• Technical analysis highlights encouraging stock price momentum, support and resistance levels, and buy signals from moving averages, all contributing to the recent bullish market movement.

12.05.2026 - AMLX Stock was up 8.5%

• AMLX stock showed significant bullish momentum today.
• The positive market sentiment can be attributed to the excitement surrounding the upcoming Phase 3 readout for avexitide, focusing on PBH.
• Investors may view the company's emphasis on rare disease commercialization and potential ALS treatments favorably.
• Recent stock options grants to directors could be interpreted as a vote of confidence in AMLX's future, bolstering the overall optimistic outlook for the company.

11.05.2026 - AMLX Stock was down 5.0%

• Today's decline in AMLX stock could be linked to investors taking profits following a period of positive developments and excitement regarding the Phase 3 readout for avexitide expected in Q3 2026.
• The announcement of directors receiving a substantial number of stock options at a strike price of $14.31 per share might have also contributed to the stock's downward pressure, potentially raising concerns about dilution among current shareholders.
• Despite the promising advancements in the company's drug pipeline and commercial strategies, today's market sentiment could have been swayed by short-term factors leading to the bearish movement in AMLX stock.

05.05.2026 - AMLX Stock was up 6.0%

• Key proposals at the Annual Meeting of Stockholders, including the election of new directors and the ratification of the independent accounting firm, likely boosted investor confidence in the company's governance and strategic direction.
• Analysts' optimism about Amylyx Pharmaceuticals' growth prospects, particularly in the post bariatric hypoglycemia (PBH) and neurodegeneration pipeline, may have attracted investors looking for long-term opportunities in the pharmaceutical industry.
• Progress in the pivotal Phase III LUCIDITY trial for avexitide, alongside potential future revenues and a positive estimated fair value per share, could have contributed to the bullish sentiment surrounding AMLX stock today.

25.05.2026 - AMLX Stock was up 6.9%

• Amylyx Pharmaceuticals stock surged to a 52-week high following positive updates about its ALS drug, AMX0114, showing no serious safety issues in the Phase 1 LUMINA trial.
• The disclosure of presenting data from the trial at the ENCALS Meeting 2026 likely bolstered investor confidence in the company's drug pipeline.
• A financial institution maintaining a Buy rating and raising the target price to $23 also contributed to the optimistic sentiment, indicating strong market expectations for Amylyx Pharmaceuticals' future performance.
• Despite concerns about overvaluation, the encouraging developments surrounding the ALS drug and analyst positivity drove the stock to new highs, demonstrating investor enthusiasm for the company's potential breakthroughs in the medical field.

25.05.2026 - AMLX Stock was up 9.1%

• AMX0114 displaying no severe safety concerns in the Phase 1 LUMINA trial probably enhanced investor confidence in Amylyx Pharmaceuticals.
• Favorable data presentation at the ENCALS Meeting 2026 suggests progress in AMX0114's development, contributing to the positive market momentum.
• Goldman Sachs' choice to uphold a Buy rating and elevate the target price to $23 mirrors an optimistic view on the company's future, further bolstering positive sentiment towards AMLX.
• Overall, the combination of promising trial outcomes, heightened target price, and optimistic analyst outlook likely propelled Amylyx Pharmaceuticals' stock surge today.

02.05.2026 - AMLX Stock was down 5.0%

• The recent downward trend in AMLX's stock may be linked to investors taking profits following a substantial price surge in the past year.
• While news of insider purchasing by director Karen Firestone was positive, market response may have been negative due to concerns about upcoming commercial launch obstacles and the requirement for additional capital for pipeline development.
• Uncertainties surrounding the success of the pivotal Phase III LUCIDITY trial for avexitide, a significant pipeline candidate, might also have contributed to the stock's decline.
• In conclusion, despite AMLX's strong long-term outlook with its innovative pipeline, short-term market sentiment and uncertainties could have influenced the current bearish movement.